Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Abstract Background Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduc...